Laxogenin

Laxogenin is a brassinosteroid, a class of plant steroid hormone involved in plant growth regulation, originally isolated from Smilax sieboldii. Brassinosteroids are structurally analogous to animal steroid hormones but function through entirely different plant-specific pathways.

The material sold in supplements is generally 5-alpha-hydroxy laxogenin, a semi-synthetic derivative rather than the plant compound itself. This distinction is frequently blurred in marketing that emphasises natural plant origin.

Product quality in this category is a serious and documented problem. Independent analyses of laxogenin-labelled products have repeatedly found either negligible amounts of the claimed compound or, more concerning, undeclared synthetic anabolic agents. Regulators in several countries have taken enforcement action against products in this space.

The proposed mechanism is an increase in protein synthesis without androgen receptor binding, which is the basis for marketing it as non-hormonal. Preclinical work on brassinosteroids in rodents has reported anabolic-like effects and influence on protein synthesis pathways.

Proposed routes include effects on the Akt/mTOR pathway and reductions in protein degradation. Some sources also suggest influence on cortisol, though this rests on very limited data.

It is important to be clear that no mechanism has been established in humans. There is no published human pharmacokinetic work describing absorption, distribution or metabolism of laxogenin, so even the basic question of whether an oral dose reaches muscle tissue in meaningful quantity is unanswered.

There are no published human clinical trials of laxogenin. That is the central fact and it should not be softened. The claims made for it derive from rodent research on brassinosteroids generally, not from studies of this compound in people.

The frequently cited figure comparing its anabolic activity favourably to prescription steroids appears to originate from marketing material rather than from a traceable published study, and should be treated accordingly.

User reports of strength gains are complicated by the adulteration problem. Where products have been found to contain undeclared synthetic anabolic agents, positive user experience may reflect those undisclosed compounds rather than laxogenin. This makes anecdotal evidence particularly unreliable in this category.

There is no human safety data for laxogenin. As with efficacy, the absence of evidence should not be read as evidence of safety.

The more immediate concern is not the compound but the category. There are reports of liver-related adverse effects associated with products sold as laxogenin, and in at least some cases analysis found undeclared synthetic compounds present. The risk being taken with such a product is not the risk described on the label.

Anyone using a product in this category should treat unexplained fatigue, yellowing of the skin or eyes, dark urine or abdominal pain as a reason to stop immediately and seek medical assessment.